research reports and media, page-4318

Mango, I agree. Maybe I have this wrong but in the past I always got the sense that PAR shy'ed away from the tougher questions.


But if they are genuine, if they have a great product....if they believe they are really attacking this in the right way...then mate, they have nothing to be afraid of.

I have always said, there should be no question they cant answer...I have always said, give us more question time.


I see that Paul is attacking those tougher questions head on nowadays.

This is the spirit we need to have. The data is supreme, it's infalible. There is nothing else out there that does what we can do that has such a massive broad base. Let me give you just one example.


OARSI 2023, Denver Colorado. It was the Pre OARSI Symposium, known as CTS. (Clinical Trial Symposium).

It was auspicious as it is company invite only. Only the OARSI council will invite who they deem to be worthy.

The 11 BEST Pharmas in the world in the OA space. We were one of them.


NOT A SINGLE ONE OF THOSE OTHER 10 HAD ANY SYNOVIUM DATA/STUDY.

Not one...just us.


There were two companies that stated "We wished that we had done a study that included synovial observational data".

I was there, this is not third party information.


008 is the study of the century, It is THE study that will cause us to pivot.
My views only, don't rely on one poster, your own research is required.




There is nothing out there that can SAFELY address not only OA but inflammation itself.

Throw Macular degeneration at Paul.

Throw meaninal side effects...heck even throw that we are running out of cash...it's not phasing him.

Why.



Because he knows what's coming?

He knows the chance of success?

He knows that our drug does not elicit SAE's

He knows that some 90% get some benefit.


Did someone say 98% chance of success based on stats?

That's sats. Pure and simple.



My views.




Spec statements in this post. No advice, there are still risks, they can be large risks. There is no 100% guarantee of success no matter what. This investment is of a spec nature.